These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 413639)

  • 1. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria.
    Wahdan MH; Sallam SA; Hassan MN; Abdel Gawad A; Rakha AS; Sippel JE; Hablas R; Sanborn WR; Kassem NM; Riad SM; Cvjetanović B
    Bull World Health Organ; 1977; 55(6):645-51. PubMed ID: 413639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine.
    Wahdan MH; Rizk F; el-Akkad AM; el-Ghoroury AA; Hablas R; Girgis NI; Amer A; Boctar W; Sippel JE; Gotschlich EC; Triau R; Sanborn WR; Cvjetanović B
    Bull World Health Organ; 1973 Jun; 48(6):667-73. PubMed ID: 4206451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial of a serogroup A meningococcus polysaccharide vaccine in Nigeria.
    Sanborn WR; Bencić Z; Cvjetanović B; Gotschlich EC; Pollock TM; Sippel JE
    Prog Immunobiol Stand; 1971; 5():497-505. PubMed ID: 4633977
    [No Abstract]   [Full Text] [Related]  

  • 4. A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A.
    Erwa HH; Haseeb MA; Idris AA; Lapeyssonnie L; Sanborn WR; Sippel JE
    Bull World Health Organ; 1973; 49(3):301-5. PubMed ID: 4211056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
    Peltola H; Mäkelä H; Käyhty H; Jousimies H; Herva E; Hällström K; Sivonen A; Renkonen OV; Pettay O; Karanko V; Ahvonen P; Sarna S
    N Engl J Med; 1977 Sep; 297(13):686-91. PubMed ID: 408682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serogroup A N. meningitidis polysaccharide vaccine and serogroup A N. meningitidis carrier state (author's transl)].
    Bencić Z; Madarić D; Manhalter T; John V; Amsel V; Weisglass H
    Lijec Vjesn; 1978 Nov; 100(11):706-7. PubMed ID: 107385
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of meningococcal group A and C polysaccharide vaccine on nasopharyngeal carrier state.
    Stroffolini T; Angelini L; Galanti I; Occhionero M; Congiu ME; Mastrantonio P
    Microbiologica; 1990 Jul; 13(3):225-9. PubMed ID: 2125684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meningococcal vaccines.
    Bethell D; Pollard AJ
    Expert Rev Vaccines; 2002 Jun; 1(1):75-84. PubMed ID: 12908514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
    Noronha CP; Struchiner CJ; Halloran ME
    Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immune response to meningococci].
    Flaegstad T
    Tidsskr Nor Laegeforen; 1989 Jan; 109(1):33-6. PubMed ID: 2492123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada.
    De Wals P; Dionne M; Douville-Fradet M; Boulianne N; Drapeau J; De Serres G
    Bull World Health Organ; 1996; 74(4):407-11. PubMed ID: 8823963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region.
    Soriano-Gabarró M; Wolter J; Hogea C; Vyse A
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):761-74. PubMed ID: 21905785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine.
    Ambrosch F; Wiedermann G; Crooy P; George AM
    Bull World Health Organ; 1983; 61(2):317-23. PubMed ID: 6407768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing epidemiology of meningococcal invasive disease in the Czech republic caused by new clone Neisseria meningitidis C:2a:P1.2(P1.5), ET-15/37.
    Krizova P; Musilek M
    Cent Eur J Public Health; 1995 Nov; 3(4):189-94. PubMed ID: 8903519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningococcal vaccines in prevention and control of meningitis.
    Saxena SN; Rawal IJ; Tripathi KK; Gupta P
    Indian Pediatr; 1985 Jun; 22(6):453-65. PubMed ID: 3938978
    [No Abstract]   [Full Text] [Related]  

  • 16. [Preventive effectiveness of an urgent mass vaccination with purified meningococcal polysaccharide vaccine observed during a meningitis epidemic].
    Wu C
    Zhonghua Liu Xing Bing Xue Za Zhi; 1985 Dec; 6(6):344-6. PubMed ID: 3938683
    [No Abstract]   [Full Text] [Related]  

  • 17. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.
    Chandramohan D; Hodgson A; Coleman P; Baiden R; Asante K; Awine E; Owusu-Agyei S; Boutriau D; Nelson CB; Greenwood B
    Vaccine; 2007 Sep; 25 Suppl 1():A83-91. PubMed ID: 17521782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
    El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
    Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of bacterial meningitis: an overview of Cochrane systematic reviews.
    Prasad K; Karlupia N
    Respir Med; 2007 Oct; 101(10):2037-43. PubMed ID: 17706408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.